- Enterprise.
- Not disclosed
- Not disclosed
- —
- 2017
- US
Radiology
RapidAI
by RapidAI · founded 2017 · US
Imaging platform for stroke, aneurysm, aortic and pulmonary embolism care, with CT perfusion, LVO and ICH modules.
On this page
54/100Solid choice
- Regulatory & Compliance18/28
FDA cleared (7 K-numbers on record)
- Clinical Integration0/26
No EHR integrations listed
- Evidence Strength26/26
5 peer-reviewed papers
- Vendor & Market14.4/18
Mid-tier funding and adoption
- Sentiment & Transparency2.5/14
Pricing on request, no public amounts
▸ Show all 11 dimensions▾ Hide dimension detail
- FDA clearance18/18
FDA cleared (7 K-numbers on record)
- HIPAA / SOC2 / BAA0/10
No public HIPAA/SOC2/BAA attestation
- EHR integrations (count)0/14
No EHR integrations listed
- Top-3 EHR coverage (Epic / Oracle / Athena)0/8
None of the top-3 EHRs covered
- Bidirectional write-back0/4
No bidirectional write-back documented
- Peer-reviewed papers18/18
5 peer-reviewed papers
- RCT / meta-analysis / systematic review8/8
1 RCT/Meta-Analysis/Systematic Review
- Funding & adoption signal8/12
Mid-tier funding and adoption
- Years in market6/6
Founded 2017 (9 years)
- Clinician sentiment (Reddit)0/9
No clinician sentiment data available
- Pricing transparency3/5
Pricing on request, no public amounts
Imaging platform for stroke, aneurysm, aortic and pulmonary embolism care, with CT perfusion, LVO and ICH modules.
Free tier available.
Bottom line
RapidAI sells software that reads stroke imaging, mainly CT perfusion, CT angiography and non-contrast CT, and alerts the stroke team to large vessel occlusions and haemorrhage. The company holds a long list of FDA 510(k) clearances, going back to 2013. It suits a thrombectomy-capable or primary stroke centre that wants perfusion maps and LVO alerts in one platform. A small hospital without CT perfusion or a neurointerventional pathway will find less to use, and any buyer should know that the strongest head-to-head claim comes from a study the vendor promotes.
What is RapidAI and who sells it?
RapidAI was formerly iSchemaView, and the legal name on FDA records is iSchemaView, Inc. The first Rapid clearance on the FDA record is dated 4 October 2013. Cofounder Greg Albers is named in the company's release on Rapid LVO, and third-party profiles list Karim Karti as CEO.
Funding is about US$100M in total per aggregators: a $25M Series B in September 2020 led by Lennertz & Co and a $75M Series C led by Vista Credit Partners. Crunchbase lists an acquisition of EndoVantage.
What does it do?
The stroke suite covers Rapid CTP perfusion, CTA, ASPECTS scoring, LVO detection and ICH detection on non-contrast CT, with a mobile app that shows case summaries. Other modules cover aneurysm, aortic disease and pulmonary embolism. The homepage now sells a broader enterprise platform that also includes radiology and life-sciences offerings, with analytics and a connector for third-party AI.
The company says its Rapid LVO tool delivers results in as few as 3 minutes with 97% sensitivity and 96% specificity (2020 release, vendor claim). The homepage claims use in more than 2,500 hospitals in over 100 countries and "30 FDA-cleared modules", which is marketing language.
What are its FDA clearances?
The FDA database lists these 510(k) records, all with the applicant Ischemaview, Inc.:
- K121447, Rapid, October 2013, product code LLZ
- K182130, December 2018, LLZ
- K193087, Rapid ICH, March 2020, QAS
- K200760, Rapid ASPECTS, June 2020, POK
- K200941, Rapid LVO, July 2020, QAS (computer-assisted triage and notification)
- K213165, February 2022, LLZ and QIH
- K233512, Rapid 6.0, January 2024, QIH
The company claims 30 cleared modules, and the database records above cover fewer than that.
The app mentions an EMR integration but names no EHR. PACS and DICOM viewer integration is claimed in general terms, and the only security statement is a line about enterprise-grade security with no SOC 2 or HITRUST attestation.
What does the evidence say?
A 2026 scoping review in Medicina (PMID 41901663) covering Brainomix e-Stroke, Aidoc, RapidAI and Viz.ai reported proximal LVO sensitivity of 78 to 97%, with more variable results for distal and posterior occlusions. In a small Aidoc versus RapidAI comparison it cites, true-positive rates were 78% against 74%, with false negatives of 22 to 26%.
A 2024 AJNR study (PMID 38346817) compared the CT perfusion output of RapidAI and Viz.ai in acute ischemic stroke and found the volumes are not interchangeable. A 2022 study compared Brainomix and RapidAI for ASPECTS, LVO and CTP (J Stroke Cerebrovasc Dis, PMID 35994882), and a 2022 paper in J Neurointerv Surg (PMID 33795483) linked the Rapid mobile app to treatment times in LVO.
The DUEL study (AJNR, May 2026) reviewed about 1,590 code strokes and reported that RapidAI detected 98% of confirmed LVOs against 73% for Viz.ai. It was retrospective, single centre and promoted by RapidAI.
How much does RapidAI cost?
RapidAI sells enterprise licences at hospital level and lists no price, trial or refund terms (as of October 2026). Expect a quote.
How does it compare?
Viz.ai, Brainomix, Aidoc, Methinks and Nicolab are the usual alternatives. RapidAI's focus is perfusion imaging, and the AJNR comparison shows that RapidAI and Viz.ai produce different perfusion volumes from the same patients.
The verdict
A stroke centre that already relies on CT perfusion should put RapidAI on its shortlist. Before signing, ask for local validation data on your own scanners and for the current list of cleared modules with K numbers, because the single-centre DUEL result is not a basis for the purchase decision. A hospital without a perfusion workflow has little reason to start here.
Editorial review last generated October 15, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.
What it costs
Free tier only, no paid plans publicly disclosed.
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Plan | — | — | Enterprise. |
Source: vendor pricing page. Last checked October 15, 2026.
What deploys cleanly
Carries FDA 510(k) (multiple) per vendor documentation. Independent attestation review is the buyer's responsibility before clinical deployment.
Who builds it
RapidAI (RapidAI) was founded in 2017 in US, putting it 9 years into market.
What the literature says
5 peer-reviewed studies indexed on PubMed evaluate RapidAI in clinical contexts. The most relevant are shown below, ranked by editorial relevance score combining title match, study design, recency, and journal tier.
- A Comparison of CT Perfusion Output of RapidAI and Viz.ai Software in the Evaluation of Acute Ischemic Stroke.
- Bushnaq S, Hassan AE, Delora A, et al.· AJNR Am J Neuroradiol· 2024
- Automated CTP postprocessing packages have been developed for managing acute ischemic stroke. These packages use image processing techniques to identify the ischemic core and penumbra. This study aimed to investigate the agreement of decision-making rules and output derived from RapidAI and Viz.ai software packages in early and late time windows and to identify predictors of inadequate quality CTP studies. One hundred twenty-nine patients with acute ischemic stroke who had CTP performed on presentation were analyzed by RapidAI and Viz.ai. Volumetric outputs were compared between packages by p…
- Transforming Stroke Diagnosis with Artificial Intelligence: A Scoping Review of Brainomix e-Stroke, Aidoc, RapidAI, and Viz.ai.
- Dorochowicz M, Kacała A, Tołkacz A, et al.· Medicina (Kaunas)· 2026
- : Rapid diagnosis is fundamental to acute ischemic stroke management; however, access to neuroradiological expertise remains limited. This scoping review maps the diagnostic accuracy, workflow impact, and cost-effectiveness of leading AI platforms (Brainomix, Aidoc, RapidAI, and Viz.ai), characterizing industry and peer-reviewed metrics.: Following PRISMA-ScR guidelines, we searched PubMed, Cochrane Library, and HTA repositories for studies (2019-2025). Using a PICO-based framework, 29 studies were included for thematic mapping of the technological landscape.: Twenty-nine studies were include…
- Impact of RapidAI mobile application on treatment times in patients with large vessel occlusion.
- Al-Kawaz M, Primiani C, Urrutia V, et al.· J Neurointerv Surg· 2022
- Current efforts to reduce door to groin puncture time (DGPT) aim to optimize clinical outcomes in stroke patients with large vessel occlusions (LVOs). The RapidAI mobile application (Rapid Mobile App) provides quick access to perfusion and vessel imaging in patients with LVOs. We hypothesize that utilization of RapidAI mobile application can significantly reduce treatment times in stroke care by accelerating the process of mobilizing stroke clinicians and interventionalists. We analyzed patients presenting with LVOs between June 2019 and October 2020. Thirty-one patients were treated between…
- Comparison of automated ASPECTS, large vessel occlusion detection and CTP analysis provided by Brainomix and RapidAI in patients with suspected ischaemic stroke.
- Mallon DH, Taylor EJR, Vittay OI, et al.· J Stroke Cerebrovasc Dis· 2022
- The ischaemic core and penumbra volumes derived from CTP aid the selection of patients with an arterial occlusion for mechanical thrombectomy. Different post-processing software packages may give different CTP outputs, potentially causing variable patient selection for mechanical thrombectomy. The study aims were, firstly, to assess the correlation in CTP outputs from software packages provided by Brainomix and RapidAI. Secondly, the correlation between automated ASPECTS and neuroradiologist-derived ASPECTS and accuracy in detecting large vessel occlusion was assessed. This retrospective stud…
- Systematic Review of Radiomics and Artificial Intelligence in Intracranial Aneurysm Management.
- Owens MR, Tenhoeve SA, Rawson C, et al.· J Neuroimaging· 2025
- Intracranial aneurysms, with an annual incidence of 2%-3%, reflect a rare disease associated with significant mortality and morbidity risks when ruptured. Early detection, risk stratification of high-risk subgroups, and prediction of patient outcomes are important to treatment. Radiomics is an emerging field using the quantification of medical imaging to identify parameters beyond traditional radiology interpretation that may offer diagnostic or prognostic significance. The general radiomic workflow involves image normalization and segmentation, feature extraction, feature selection or dimens…
Other radiology
See the full radiology ranking
Siemens Healthineers AI-Rad Companion
by Siemens Healthineers
AI-Rad Companion: Chest CT, Chest X-ray, Brain MR, Prostate MR and Organs RT (radiotherapy contouring) modules, delivered through teamplay.
No public price on the vendor page.|FDA 510(k) (multiple) / CE Mark (MDD/MDR. MDR status not verified)
GE HealthCare AI Suite
by GE HealthCare
Portfolio of separately cleared AI-enabled GE HealthCare devices and software, including AIR Recon DL, Sonic DL, Critical Care Suite, Caption AI and icobrain.
No public price. Products are sold with scanners or as scanner options, on enterprise quotes.|FDA 510(k) (multiple)
Aidoc
by Aidoc
Clinical AI platform (aiOS) with FDA-cleared triage, notification and quantification algorithms for radiology and neurovascular care.
Private offer only. No trial is stated.|FDA 510(k) (multiple) / EU MDR 2017/745
Viz.ai
by Viz.ai
Care coordination platform with FDA-cleared imaging AI for stroke, vascular and cardiac conditions.
No public price. Sold to health systems after a demo request.|FDA 510(k) (multiple) / FDA De Novo (ContaCT, Viz HCM)